Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells

(2014) Y Zou et al.   BRITISH JOURNAL OF CANCER

Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape

(2014) A. C. Anderson   Cancer Immunology Research

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors

(2014) Clara E. Jäkel et al.   Journal of Immunology Research

The co-receptor BTLA negatively regulates human V 9V 2 T-cell proliferation: a potential way of immune escape for lymphoma cells

(2013) J. Gertner-Dardenne et al.   BLOOD

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

(2012) D. M. Benson et al.   BLOOD

Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells

(2012) Claudia Schlimper et al.   Clinical & Developmental Immunology

A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission

(2012) Yeh-Ching Linn et al.   CYTOTHERAPY

Human interferon-alpha increases the cytotoxic effect of CD56+cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines

(2012) Ludovic Durrieu et al.   CYTOTHERAPY

New adoptive immunotherapy strategies for solid tumours with CIK cells

(2012) Sharmilan Thanendrarajan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

(2012) Giulia Mesiano et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Selective Blockade of Herpesvirus Entry Mediator-B and T Lymphocyte Attenuator Pathway Ameliorates Acute Graft-versus-Host Reaction

(2012) M.-L. del Rio et al.   JOURNAL OF IMMUNOLOGY

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

(2011) Ginna G. Laport et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies

(2011) Y-C Linn et al.   BONE MARROW TRANSPLANTATION

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells

(2011) Eva Rettinger et al.   CYTOTHERAPY

The CD4-like molecule LAG-3, biology and therapeutic applications

(2010) Sophie Sierro et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors

(2010) V. Marin et al.   HAEMATOLOGICA

The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR

(2010) Jeroen Van Bergen et al.   IMMUNOLOGY

TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines

(2009) William D. Hastings et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes

(2009) Marta Franceschetti et al.   EXPERIMENTAL HEMATOLOGY

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

(2008) R. Nishimura et al.   BLOOD

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell

(2008) Yeh C. Linn et al.   IMMUNOLOGY

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes

(2007) Eva S.K. Rijkers et al.   MOLECULAR IMMUNOLOGY